The Asia Summit on Global Health (ASGH), scheduled for May 11-12, 2026, in Hong Kong, aims to tackle critical commercialization challenges facing biotech executives, investors, and R&D leaders. The summit’s theme, “Fuelling Healthcare Breakthroughs,” emphasizes the need to bridge innovative scientific advancements with effective commercial strategies across various sectors, including AI, advanced therapeutics, and the burgeoning silver economy.

The significance of ASGH lies in its focus on building a robust framework for pandemic preparedness and leveraging China’s 15th Five-Year Plan, which prioritizes biomanufacturing and innovation. Key discussions will feature prominent experts like Prof Ibrahim Abubakar, who will address the importance of real-time data sharing and early-warning technologies. Additionally, sessions on digital health and AI innovations will explore practical strategies for transitioning from experimental models to clinical applications, highlighting the necessity for sustainable business models that yield measurable outcomes.

A major takeaway from ASGH is its potential to redefine the landscape for cell and gene therapies (CGT) and the silver economy. With the global population aged 60 and older projected to reach 2.1 billion by 2050, the summit will present actionable insights on translating longevity science into commercial viability. The event promises to connect capital with innovation through targeted investor meetings and showcases, making it a pivotal opportunity for biotech professionals to secure funding and partnerships that can accelerate the development and scaling of transformative healthcare solutions.

Source: fiercebiotech.com